FDA Approves Zejula as Late-Line Treatment for Recurrent Ovarian Cancer Patients

FDA Approves Zejula as Late-Line Treatment for Recurrent Ovarian Cancer Patients
The U.S. Food and Drug Administration (FDA) has approved Zejula (niraparib) as a late-line treatment for women with advanced ovarian, fallopian tube, or primary peritoneal cancer who have tumors defective in DNA repair, a status termed “homologous recombination deficiency” (HRD), and have received at least three prior courses of chemotherapy. Zejula is an oral PARP inhibitor marketed by Tesaro, a subsidiary of GlaxoSmithKline (GSK). It works by blocking the activity of PARP enzymes, which are involved in DNA repair. By blocking the activity of these enzymes, Zejula prevents cancer cells from repairing their DNA, thereby eventually eliminating them. The medication had previously been approved in the U.S. and Europe as a maintenance therapy for women with recurrent and high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer, who are responding at least partially to platinum-based chemothera
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *